Current Report Filing (8-k)
December 06 2018 - 3:45PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest reported):
November 30, 2018
Novo
Integrated Sciences, Inc.
(Exact
name of small business issuer as specified in its charter)
|
Nevada
|
|
333-109118
|
|
59-3691650
|
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
Number)
|
11120
NE 2nd Street, Suite 200, Bellevue, WA 98004
(Address
of principal executive offices)
(206)
617-9797
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.)
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CF$ 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
November 30, 2018, Novo Integrated Sciences, Inc. (the “Company”) entered into an employment agreement (the “Employment
Agreement”) with Christopher David, the Company’s President and a member of the board of directors, effective December
1, 2018. The Employment Agreement terminates on July 31, 2019, subject to the termination provisions contained in the Employment
Agreement.
Pursuant
to the terms of the Employment Agreement, Mr. David agreed to serve as the Company’s President. In consideration thereof,
the Company agreed to pay Mr. David a monthly salary of $8,000.
Pursuant
to the terms of the Employment Agreement, the Company may terminate Mr. David at any time, with or without Cause (as defined below);
provided, however, that if the Company terminates Mr. David without Cause the Company will continue to owe Mr. David his monthly
salary through July 31, 2019.
“Cause”
means Mr. David must have (i) been willful, gross or persistent in his inattention to his duties or he committed acts which constitute
willful or gross misconduct and, after written notice of the same, has been given the opportunity to cure the same within 30 days
after such notice, or (ii) been found guilty of having committed actual fraud against the Company.
The
foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference
to the full text of the Employment Agreement, a copy of which is filed as Exhibit 10.1 to this current report on Form 8-K and
is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
Novo
Integrated Sciences, Inc.
|
|
|
|
|
|
Dated:
December 6, 2018
|
By:
|
/s/
Robert Mattacchione
|
|
|
|
Robert
Mattacchione
|
|
|
|
Chief
Executive Officer
|